Reactive oxygen species in colorectal cancer adjuvant therapies
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, ISSN: 0925-4439, Vol: 1870, Issue: 2, Page: 166922
2024
- 8Citations
- 10Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Investigators at Sichuan University Detail Findings in Colon Cancer (Reactive Oxygen Species In Colorectal Cancer Adjuvant Therapies)
2024 FEB 01 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Investigators discuss new findings in Oncology - Colon Cancer. According
Review Description
Colorectal cancer (CRC), a prevalent global malignancy, often necessitates adjuvant therapies such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy to mitigate tumor burden in advanced stages. The efficacy of these therapies is significantly influenced by reactive oxygen species (ROS). Previous research underscores the pivotal role of ROS in gut pathology, targeted therapy, and drug resistance. ROS-mediated CRC adjuvant therapies encompass a myriad of mechanisms, including cell death and proliferation, survival and cell cycle, DNA damage, metabolic reprogramming, and angiogenesis. Preliminary clinical trials have begun to unveil the potential of ROS-manipulating therapy in enhancing CRC adjuvant therapies. This review aims to provide a comprehensive synthesis of studies exploring the role of ROS in CRC adjuvant therapies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0925443923002880; http://dx.doi.org/10.1016/j.bbadis.2023.166922; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85177202620&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37898425; https://linkinghub.elsevier.com/retrieve/pii/S0925443923002880; https://dx.doi.org/10.1016/j.bbadis.2023.166922
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know